tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Dermatitis D003872 30 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pharyngitis D010612 2 associated lipids
Shock D012769 11 associated lipids
Erythema D004890 22 associated lipids
Dermatomycoses D003881 17 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Cholelithiasis D002769 16 associated lipids
Fever D005334 35 associated lipids
Amenorrhea D000568 4 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hyperlipidemias D006949 73 associated lipids
Shock, Septic D012772 11 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Cough D003371 19 associated lipids
Paraproteinemias D010265 2 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Translocation, Genetic D014178 20 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Ovarian Cysts D010048 4 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Cardiomegaly D006332 31 associated lipids
Hypertension, Renal D006977 9 associated lipids
Metaplasia D008679 7 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Tachycardia D013610 7 associated lipids
Cicatrix D002921 9 associated lipids
Neutropenia D009503 15 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Urticaria D014581 13 associated lipids
Behcet Syndrome D001528 7 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Thrombophlebitis D013924 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
HIV Seropositivity D006679 15 associated lipids
Uveitis D014605 14 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lanford RE et al. Comparison of tamarins and marmosets as hosts for GBV-B infections and the effect of immunosuppression on duration of viremia. 2003 Virology pmid:12832204
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Mahalingam R et al. Simian varicella virus reactivation in cynomolgus monkeys. 2007 Virology pmid:17651776
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Mistríková J et al. Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). 1999 Viral Immunol. pmid:10532652
Gambarino S et al. Human Cytomegalovirus Impact on mir-146a Expression Levels in Kidney Transplant Patients. 2016 Viral Immunol. pmid:27077822
Shen ZY et al. Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. 2012 Viral Immunol. pmid:22946668
Mortola E et al. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. 1998 Vet. Res. Commun. pmid:10066129
Tanaka Y et al. Suppression of feline coronavirus replication in vitro by cyclosporin A. 2012 Vet. Res. pmid:22546085
Kano R et al. Treatment of sterile panniculitis in a dog. 2004 Vet. Rec. pmid:15134169
Ofri R et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. 2009 Vet. J. pmid:17950639
Sestak K et al. Tacrolimus-FK506 induced immunosuppression in gnotobiotic piglets. 2000 Vet. Immunol. Immunopathol. pmid:11137126
Marsella R et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. 2004 Vet. Dermatol. pmid:15500481
Mauldin EA et al. Proliferative and necrotizing otitis externa in four cats. 2007 Vet. Dermatol. pmid:17845627
Banovic F et al. Tacrolimus therapy for dermal arteritis of the nasal philtrum refractory to surgery and anti-inflammatory therapy (doxycycline/niacinamide and topical fluocinolone) in a dog. 2018 Vet. Dermatol. pmid:28990239
Hilton H et al. Evaluation of four topical preparations for the treatment of cannon hyperkeratosis in a horse. 2008 Vet. Dermatol. pmid:19055613
Marsella R and Nicklin CF Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. 2002 Vet. Dermatol. pmid:12174182
Banovic F et al. Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus. 2017 Vet. Dermatol. pmid:28439997
Rosenkrantz WS Pemphigus: current therapy. 2004 Vet. Dermatol. pmid:15030557
Olivry T et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. 2010 Vet. Dermatol. pmid:20456716
Marsella R et al. Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic) on intradermal skin test reactivity in atopic dogs. 2004 Vet. Dermatol. pmid:15305928
Lehner GM and Linek M A case of vesicular cutaneous lupus erythematosus in a Border collie successfully treated with topical tacrolimus and nicotinamide-tetracycline. 2013 Vet. Dermatol. pmid:24118370
Kelley LS et al. Safety and tolerability of 0.1% tacrolimus solution applied to the external ear canals of atopic beagle dogs without otitis. 2010 Vet. Dermatol. pmid:20609208
Bensignor E and Olivry T Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. 2005 Vet. Dermatol. pmid:15725106
Scholz FM et al. Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. 2015 Vet. Dermatol. pmid:26216245
Nell B et al. The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. 2005 Jan-Feb Vet Ophthalmol pmid:15644099
Berdoulay A et al. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. 2005 Jul-Aug Vet Ophthalmol pmid:16008701
Hafizi S et al. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. 2004 May-Jun Vascul. Pharmacol. pmid:15607500
Dissemond J et al. Successful treatment of stasis dermatitis with topical tacrolimus. 2004 VASA pmid:15623206
Woodward RS et al. The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. 2011 Value Health pmid:21315636
Christ B et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. 2001 Urology pmid:11597545
Harmon JD et al. Stuttering priapism in a liver transplant patient with toxic levels of fk506. 1999 Urology pmid:10754131
Chkhotua AB et al. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. 2003 Urology pmid:14665344
Ebert AK et al. [Topical therapy of balanitis xerotica obliterans in childhood. Long-term clinical results and an overview]. 2007 Urologe A pmid:17994212
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Nomura T et al. Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells. 2002 Urol. Res. pmid:12086014
Hwang MT and Goldfarb DS Uric acid stones following hepatic transplantation. 2004 Urol. Res. pmid:15565437
Veroux P et al. Severe neurotoxicity in tacrolimus-treated living kidney transplantation in two cases. 2003 Urol. Int. pmid:14646448
Pichler R et al. De novo renal cell carcinoma in a kidney allograft with focus on contrast-enhanced ultrasound. 2014 Urol. Int. pmid:25115614
Naderi GH et al. Tacrolimus rescue therapy for corticosteroid-resistant and polyclonal antibody-resistant kidney allograft rejections. 2009 Urol J pmid:19241339
Freire A et al. Comparison of blood tacrolimus concentrations in liver and kidney transplant recipients using ACMIA and MEIA immunoassays. 2008 Ups. J. Med. Sci. pmid:18521804
Präst I et al. Nerve cells in transplanted pancreatic islets: no effects of cyclosporin or tacrolimus on immediate neuronal survival. 2001 Ups. J. Med. Sci. pmid:11888070
Valesky EM et al. [Postoperative pyoderma gangrenosum of Cullen]. 2007 Unfallchirurg pmid:17786400
Deleuran M et al. [Topical immune modulation and risk of cancer]. 2009 Ugeskr. Laeg. pmid:19732533
Rosenzweig M [Prescription of topical immunomodulators]. 2009 Ugeskr. Laeg. pmid:19732534
Thestrup-Pedersen K and Thomsen TF [Creams used in the treatment of children can cause cancer]. 2005 Ugeskr. Laeg. pmid:15832731
Tusgaard Petersen B et al. [Family occurrence of steroid-sensitive idiopathic nephrotic syndrome]. 2012 Ugeskr. Laeg. pmid:23153469
Mørtz CG and Deleuran MS [A case of childhood granulomatous perioral dermatitis (CGPD) in a three year old boy from Madagascar]. 2008 Ugeskr. Laeg. pmid:18252166
Tümgör G et al. Fatty liver due to high levels of serum tacrolimus after liver transplantation. 2007 Apr-Jun Turk. J. Pediatr. pmid:17907528
Ismailoglu O et al. Topical application of tacrolimus prevents epidural fibrosis in a rat postlaminectomy model: histopathological and ultrastructural analysis. 2011 Turk Neurosurg pmid:22194127
Tümgör G et al. A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. 2014 Turk J Gastroenterol pmid:25599790
Dinçkan A et al. Evaluation of the first 100 liver transplantations. 2008 Turk J Gastroenterol pmid:18386237
Bajetta E et al. Merkel cell carcinoma after liver transplantation: a case report. 2007 May-Jun Tumori pmid:17679476
Vennarecci G et al. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. 2003 Jul-Aug Tumori pmid:12903579
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Nashan B et al. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. 2015 Trials pmid:25873064
Snyder SH et al. Neural actions of immunophilin ligands. 1998 Trends Pharmacol. Sci. pmid:9509898
Liu J FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. 1993 Trends Pharmacol. Sci. pmid:7692652
Chang JY et al. FK506 and rapamycin: novel pharmacological probes of the immune response. 1991 Trends Pharmacol. Sci. pmid:1710854
Cardenas ME et al. Signal-transduction cascades as targets for therapeutic intervention by natural products. 1998 Trends Biotechnol. pmid:9807840
Kunz J and Hall MN Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. 1993 Trends Biochem. Sci. pmid:7694398
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. 2003 Apr-May TreatmentUpdate pmid:17216847
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Lawsin L and Light JA Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. 2003 Transplantation pmid:12544890
Furukawa H et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. 2000 Transplantation pmid:10670633
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Toso C et al. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. 2003 Transplantation pmid:14557767
Vu MD et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. 2003 Transplantation pmid:12792496
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Khanna AK Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. 2000 Transplantation pmid:10972232
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
Marcén R et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. 2006 Transplantation pmid:16570003
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Alonso-Arias R et al. CD127(low) expression in CD4+CD25(high) T cells as immune biomarker of renal function in transplant patients. 2009 Transplantation pmid:19667968
Galliford J et al. ABO incompatible living renal transplantation with a steroid sparing protocol. 2008 Transplantation pmid:18852653
Dickenmann MJ et al. Blood eosinophilia in tacrolimus-treated patients: an indicator of Pneumocystis carinii pneumonia. 1999 Transplantation pmid:10589963
Kaufman DB et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. 1995 Transplantation pmid:7541579
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Thorp M et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. 2000 Transplantation pmid:10762229
Amundsen R et al. Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. 2009 Transplantation pmid:19384170
Jun KR et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. 2009 Transplantation pmid:19384171
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Egli A et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. 2013 Transplantation pmid:23274966
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Gruessner RW et al. Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. 1998 Transplantation pmid:9701258
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Konrad T et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. 2000 Transplantation pmid:10852599
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561